Analysts have pointed out the change from "significantly undervalues" to "undervalues," and the absence of the word "unanimous" from the AstraZeneca board's official rebuff of Pfizer's latest offer. The media is polling top AstraZeneca shareholders, looking for hints about which might push for deal–and how hard.
written on 19.05.2014